Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Gilead Sciences Inc
GILD | US
130.40
USD-3.24
-2.42%
GILD | US
Loading StockChartView...
About Gilead Sciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
130.40
Open
131.54
High
132.32
Low
129.28
Gilead Sciences Inc. a biopharmaceutical company discovers develops and commercializes medicines in the areas of unmet medical need in the United States Europe and internationally. The company provides Biktarvy Genvoya Descovy Odefsey Truvada Complera/ Eviplera Stribild and Atripla products for the treatment of HIV/AIDS; Veklury an injection for intravenous use for the treatment of coronavirus disease 2019; and Epclusa Harvoni Vosevi Vemlidy and Viread for the treatment of viral hepatitis. It also offers Yescarta Tecartus Trodelvy and Zydelig products for the treatment of oncology; Letairis an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences Inc. has collaboration agreements with Arcus Biosciences Inc.; Merck & Co Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics Inc.; Tango Therapeutics Inc.; Jounce Therapeutics Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco Inc.; Dragonfly Therapeutics Inc.; and Merck & Co Inc. The company was incorporated in 1987 and is headquartered in Foster City California.
View LessGILD | US
Risk
20.5
Sharpe
0.73
Luna's Score
52/100
Recommendation
Hold
Luna says (GILD | US)
What's Working
Low 6-Month Volatility (<30%)
Largecap (10B - 200B USD)
Good Dividend Yield (2% <= Dividend Yield <= 8%)
Low Market Beta (-0.4 to 0.8)
Strong Operating Margin (> 25%)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
Weak P/E, and PEG ratio indicator
High Debt to Equity (> 0.75)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
17.5%1 month
20.5%3 months
27.1%6 months
26.5%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
105.76
Fwd. PE
12.18
Price to book
5.95
Debt to equity
1.28
Debt to assets
0.44
Ent. to EBITDA
24.54
Ent. to rev.
4.65
PEG
0.52
Other Fundamentals
EBITDA
13.46B
MarketCap
162.35B
MarketCap(USD)
162.35B
Div. yield
3.53
Op. margin
38.72
Erngs. growth
55.40
Rev. growth
5.40
Ret. on equity
5.26
Short ratio
2.24
Short perc.
1.43
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
13.00
Range1M
13.69
Range3M
28.01
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.17
Price X volume
774.37M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 24.54 | 0.53 | Expensive |
| Ent. to Revenue | 4.65 | 3,967.00 | Cheaper |
| PE Ratio | 105.76 | 41.03 | Expensive |
| Price to Book | 5.95 | 15.55 | Cheaper |
| Dividend Yield | 3.53 | 2.20 | Leader |
| Std. Deviation (3M) | 27.05 | 72.80 | Lower Risk |
| Debt to Equity | 1.28 | -1.23 | Expensive |
| Debt to Assets | 0.44 | 0.25 | Expensive |
| Market Cap | 162.35B | 3.66B | Market Leader |
